REHOVOT, Israel, April 20, 2017 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical company developing drug-device combinations for central nervous system (CNS) disorders, today announced that the company’s CEO, Oded S. Lieberman, PhD, will ring The Nasdaq Stock Market Opening Bell in New York on Friday, April 21, 2017.
A live stream of the ceremony will be available at http://livestream.com/nasdaq/live from approximately 9:15 a.m. ET until 9:30 a.m. ET.
NeuroDerm will also host its first Investor Day in New York from 10:30 a.m. to 1:30 p.m. on April 21, and will sponsor and participate in the 23rd Parkinson’s Unity Walk in Central Park on Saturday, April 22.
The Parkinson's Unity Walk (PUW), a grassroots organization, began in 1994 through the dedicated efforts of patients, families, support groups, and friends who were affected by Parkinson's disease. Their main goal was to raise awareness and funds for research to find a cure for Parkinson's. Over the last twenty-two years, the Unity Walk has grown from 200 participants in the first event to approximately 9,000 participants in the 2016 Walk. The funds raised for the Walk have also dramatically increased with each passing year. In 1994, the Unity Walk raised $16,000 in research funds, and in 2016 over $1,400,000 was raised for Parkinson’s research. Donations from the Unity Walk have gone to support research at several major U.S. Parkinson's foundations. Additional information is available at: http://www.unitywalk.org/.
“April is Parkinson’s disease awareness month, and we are pleased to have multiple opportunities over the next few days to help support the Parkinson’s community and share our commitment to developing novel therapies that have the potential to transform the treatment of this debilitating disease,” said Dr. Lieberman. “The courage and determination of the Parkinson’s patients who participate in the Unity Walk inspire everyone at NeuroDerm to remain diligent in our efforts to complete the clinical development of our lead product candidate, ND0612, and prepare to submit regulatory filings for this innovative treatment in the United States and Europe.”
NeuroDerm is a clinical-stage pharmaceutical company developing drug-device combinations for central nervous system (CNS) disorders that are designed to overcome major deficiencies of current treatments and achieve enhanced clinical efficacy through continuous, controlled administration. NeuroDerm has three product candidates in different stages of development that offer a solution for almost every Parkinson’s disease patient from the moderate to the very severe stage of the disease. NeuroDerm has developed a line of levodopa and carbidopa (LD/CD) product candidates administered through small belt pumps that deliver a continuous, controlled dose of LD/CD. The LD/CD product candidates are ND0612L and ND0612H, which are used for treatment of moderate and advanced Parkinson’s disease patients, respectively, and which are delivered subcutaneously. In addition, NeuroDerm is developing ND0701, a novel subcutaneously delivered apomorphine formulation for patients who suffer from moderate to severe Parkinson’s disease and who do not respond well to LD/CD. NeuroDerm is headquartered in the Weizmann Science Park in Rehovot, Israel.
Oded S. Lieberman, PhD, CEO
Tel.: +972-8-946 2729
Cell: +1-617-517 6077
U.S. Investor Contact:
Lazar Partners Ltd.